A novel selective multikinase inhibitor of ROCK and MRCK effectively blocks cancer cell migration and invasion

Cancer Letters

Volumn 354, Issue 2, 2014, Pages 299-310

  Kale, Vijay Pralhad ^a   Hengst, Jeremy A ^a   Desai, Dhimant H ^a   Dick, Taryn E ^a   Choe, Katherine N ^a   Colledge, Ashley L ^a   Takahashi, Yoshinori ^a   Sung, Shen Shu ^a   Amin, Shantu G ^a   Yun, Jong K ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Cancer; Migration; MRCK; Multikinase inhibitor; ROCK; Stress fibers

Indexed keywords

2 5 [1H PYRROLO(2,3 B)PYRIDINE 3 YLMETHYLENE] 1,3 THIAZOL 4(5H)ONE; ADENOSINE TRIPHOSPHATE; ANTIMETASTATIC AGENT; MYOTONIC DYSTROPHY KINASE RELATED CDC42 BINDING KINASE; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; RHO KINASE; UNCLASSIFIED DRUG; 2-5-(1H-PYRROLO(2,3-B)PYRIDINE-3-YLMETHYLENE)-1,3-THIAZOL-4(5H)-ONE; CDC42BPA PROTEIN, HUMAN; CDC42BPB PROTEIN, HUMAN; MYOTONIC DYSTROPHY PROTEIN KINASE; ROCK1 PROTEIN, HUMAN; THIAZOLIDINE DERIVATIVE;

ARTICLE; BREAST CANCER CELL LINE; CANCER CELL; CANCER CELL LINE; CELL ASSAY; CELL FUNCTION; CELL MIGRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME INHIBITION; FIBROBLAST; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOMA CELL LINE; METASTASIS INHIBITION; NON SMALL CELL LUNG CANCER; PANCREATIC CANCER CELL LINE; PROTEIN TARGETING; STRESS FIBER; TUMOR INVASION; ANTAGONISTS AND INHIBITORS; CELL MOTION; DRUG EFFECTS; ENZYMOLOGY; NEOPLASMS; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL MOVEMENT; HUMANS; MYOTONIN-PROTEIN KINASE; NEOPLASM INVASIVENESS; NEOPLASMS; PROTEIN KINASE INHIBITORS; RHO-ASSOCIATED KINASES; THIAZOLIDINES;

EID: 84908004722     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.08.032     Document Type: Article

References (43)

1. Coussens L.M., Fingleton B., Matrisian L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002, 295:2387-2392.
2. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
3. Rath N., Olson M.F. Rho-associated kinases in tumorigenesis: re-considering ROCK inhibition for cancer therapy. EMBO Rep 2012, 13:900-908.
4. Morgan-Fisher M., Wewer U.M., Yoneda A. Regulation of ROCK activity in cancer. J. Histochem. Cytochem 2013, 61:185-198.
5. Abe H., Kamai T., Tsujii T., Nakamura F., Mashidori T., Mizuno T., et al. Possible role of the RhoC/ROCK pathway in progression of clear cell renal cell carcinoma. Biomed. Res 2008, 29:155-161.
6. Kamai T., Arai K., Sumi S., Tsujii T., Honda M., Yamanishi T., et al. The rho/rho-kinase pathway is involved in the progression of testicular germ cell tumour. BJU Int 2002, 89:449-453.
7. Kamai T., Arai K., Tsujii T., Honda M., Yoshida K. Overexpression of RhoA mRNA is associated with advanced stage in testicular germ cell tumour. BJU Int 2001, 87:227-231.
8. Kamai T., Tsujii T., Arai K., Takagi K., Asami H., Ito Y., et al. Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin. Cancer Res 2003, 9:2632-2641.
9. Kamai T., Yamanishi T., Shirataki H., Takagi K., Asami H., Ito Y., et al. Overexpression of RhoA, Rac1, and Cdc42 GTPases is associated with progression in testicular cancer. Clin. Cancer Res 2004, 10:4799-4805.
10. Wong C.C.-L., Wong C.-M., Tung E.K.-K., Man K., Ng I.O.-L. Rho-kinase 2 is frequently overexpressed in hepatocellular carcinoma and involved in tumor invasion. Hepatology 2009, 49:1583-1594.
11. Lane J., Martin T.A., Watkins G., Mansel R.E., Jiang W.G. The expression and prognostic value of ROCK I and ROCK II and their role in human breast cancer. Int. J. Oncol 2008, 33:585-593.
12. Liu S., Goldstein R.H., Scepansky E.M., Rosenblatt M. Inhibition of rho-associated kinase signaling prevents breast cancer metastasis to human bone. Cancer Res 2009, 69:8742-8751.
13. Vigil D., Kim T.Y., Plachco A., Garton A.J., Castaldo L., Pachter J.A., et al. ROCK1 and ROCK2 are required for non-small cell lung cancer anchorage-independent growth and invasion. Cancer Res 2012, 72:5338-5347.
14. Friedl P., Alexander S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell 2011, 147:992-1009.
15. Vicente-Manzanares M., Ma X., Adelstein R.S., Horwitz A.R. Non-muscle myosin II takes centre stage in cell adhesion and migration. Nat. Rev. Mol. Cell Biol 2009, 10:778-790.
16. Zhao Z.-S., Manser E. PAK and other Rho-associated kinases - effectors with surprisingly diverse mechanisms of regulation. Biochem. J. 2005, 386:201-214.
17. Ishizaki T., Naito M., Fujisawa K., Maekawa M., Watanabe N., Saito Y., et al. p160ROCK, a Rho-associated coiled-coil forming protein kinase, works downstream of Rho and induces focal adhesions. FEBS Lett 1997, 404:118-124.
18. Sahai E., Marshall C.J. Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis. Nat. Cell Biol 2003, 5:711-719.
19. Kosla J., Pankova D., Plachy J., Tolde O., Bicanova K., Dvorak M., et al. Metastasis of aggressive amoeboid sarcoma cells is dependent on Rho/ROCK/MLC signaling. Cell Commun. Signal 2013, 11:51.
20. Wyckoff J.B., Pinner S.E., Gschmeissner S., Condeelis J.S., Sahai E. ROCK- and myosin-dependent matrix deformation enables protease-independent tumor-cell invasion in vivo. Curr. Biol 2006, 16:1515-1523.
21. Wilkinson S., Paterson H.F., Marshall C.J. Cdc42-MRCK and Rho-ROCK signalling cooperate in myosin phosphorylation and cell invasion. Nat. Cell Biol 2005, 7:255-261.
22. Wolf K., Mazo I., Leung H., Engelke K., von Andrian U.H., Deryugina E.I., et al. Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J. Cell Biol 2003, 160:267-277.
23. Riento K., Ridley A.J. Rocks: multifunctional kinases in cell behaviour. Nat. Rev. Mol. Cell Biol 2003, 4:446-456.
24. Amano M., Nakayama M., Kaibuchi K. Rho-kinase/ROCK: a key regulator of the cytoskeleton and cell polarity. Cytoskeleton (Hoboken) 2010, 67:545-554.
25. Heikkila T., Wheatley E., Crighton D., Schroder E., Boakes A., Kaye S.J., et al. Co-crystal structures of inhibitors with MRCKbeta, a key regulator of tumor cell invasion. PLoS ONE 2011, 6:e24825.
26. Ito M., Nakano T., Erdodi F., Hartshorne D.J. Myosin phosphatase: structure, regulation and function. Mol. Cell. Biochem 2004, 259:197-209.
27. Yoneda A., Multhaupt H.A., Couchman J.R. The Rho kinases I and II regulate different aspects of myosin II activity. J. Cell Biol 2005, 170:443-453.
28. Liao J.K., Seto M., Noma K. Rho kinase (ROCK) inhibitors. J. Cardiovasc. Pharmacol 2007, 50:17-24.
29. Hahmann C., Schroeter T. Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity. Cell. Mol. Life Sci 2010, 67:171-177.
30. Pan P., Shen M., Yu H., Li Y., Li D., Hou T. Advances in the development of Rho-associated protein kinase (ROCK) inhibitors. Drug Discov. Today 2013, 18:1323-1333.
31. Leung T., Chen X.Q., Manser E., Lim L. The p160 RhoA-binding kinase ROK alpha is a member of a kinase family and is involved in the reorganization of the cytoskeleton. Mol. Cell. Biol 1996, 16:5313-5327.
32. Katoh K., Kano Y., Ookawara S. Rho-kinase dependent organization of stress fibers and focal adhesions in cultured fibroblasts. Genes Cells 2007, 12:623-638.
33. Routhier A., Astuccio M., Lahey D., Monfredo N., Johnson A., Callahan W., et al. Pharmacological inhibition of Rho-kinase signaling with Y-27632 blocks melanoma tumor growth. Oncol. Rep 2010, 23:861-867.
34. Somlyo A.V., Bradshaw D., Ramos S., Murphy C., Myers C.E., Somlyo A.P. Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells. Biochem. Biophys. Res. Commun 2000, 269:652-659.
35. Imamura F., Mukai M., Ayaki M., Akedo H. Y-27632, an inhibitor of Rho-associated protein kinase, suppresses tumor cell invasion via regulation of focal adhesion and focal adhesion kinase. Jpn. J. Cancer Res 2000, 91:811-816.
36. Yang X.Y., Zhang Y., Wang S.M., Shi W.J. Effect of fasudil on growth, adhesion, invasion, and migration of 95D lung carcinoma cells in vitro. Can. J. Physiol. Pharmacol 2010, 88:874-879.
37. Yang X., Di J., Zhang Y., Zhang S., Lu J., Liu J., et al. The Rho-kinase inhibitor inhibits proliferation and metastasis of small cell lung cancer. Biomed. Pharmacother 2012, 66:221-227.
38. Ying H., Biroc S.L., Li W.W., Alicke B., Xuan J.A., Pagila R., et al. The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. Mol. Cancer Ther 2006, 5:2158-2164.
39. Patel R.A., Forinash K.D., Pireddu R., Sun Y., Sun N., Martin M.P., et al. RKI-1447 is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer. Cancer Res 2012, 72:5025-5034.
40. Nakajima M., Hayashi K., Egi Y., Katayama K.-I., Amano Y., Uehata M., et al. Effect of Wf-536, a novel ROCK inhibitor, against metastasis of B16 melanoma. Cancer Chemother. Pharmacol 2003, 52:319-324.
41. Gaggioli C., Hooper S., Hidalgo-Carcedo C., Grosse R., Marshall J.F., Harrington K., et al. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat. Cell Biol 2007, 9:1392-1400.
42. Fritz G., Just I., Kaina B. Rho GTPases are over-expressed in human tumors. Int. J. Cancer 1999, 81:682.
43. Fritz G., Brachetti C., Bahlmann F., Schmidt M., Kaina B. Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters. Br. J. Cancer 2002, 87:635-644.